title: Matrix metalloproteinases, angiogenesis, and cancer: commentary re: A. C. Lockhart et al., Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin. Cancer Res., 9: 00-00, 2003.
authors.affiliation: Department of Carcinogenesis, The University of Texas M. D. Anderson Cancer Center, Smithville, Texas 78957, USA. jerundhaug@sprd1.mdacc.tmc.edu
authors.forename: Joyce E
authors.initials: JE
authors.lastname: Rundhaug
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles; D020782:Matrix Metalloproteinases / Q000378:metabolism*; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy; D009389:Neovascularization, Pathologic; D009930:Organic Chemicals
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D009930:Organic Chemicals; C422302:N-((2S)-2-mercapto-1-oxo-4-(3,4,4- trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3- dimethyl-L-Valinamide; D020782:Matrix Metalloproteinases